Option chain shows key data for DBV Technologies's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for DBV Technologies.

DBV Technologies (NASDAQ:DBVT) Stock, Option Chain

DBV Technologies

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

ABBV

ALMS

CORT

DBVT

SLRN


With tariffs sending markets reeling in the first days of the second quarter—the S&amp;P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking

3 Biopharmaceutical Stocks Bucking the Sell-Off

chart-1905225

News

DBV Technologies secured up to $306.9M to advance its Viaskin Peanut program. The funding supports FDA submission, commercialization and ongoing pediatric peanut allergy treatment research.

Why DBV Technologies (DBVT) Stock Is Skyrocketing

WallStreet.Banks.Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

MIST

PRTG

XTIA

Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA

DBV TECHNOLOGIES SA by DBV Technologies SA

Press Releases

DBV Technologies Reports Third Quarter 2024 Financial Results

DBV Technologies Announces Plan to Implement ADS Ratio Change

Information regarding the total number of voting rights and   total number of shares of the Company as of November 30, 2024

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

PARIS:DBV

Abeona Therapeutics

Anika Therapeutics

Annexon

Candel Therapeutics

Cidara Therapeutics

Cargo Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

Foghorn Therapeutics

Gossamer Bio

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Neurogene

Nuvectis Pharma

Ocugen

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Prime Medicine

Solid Biosciences

Acelyrin

2seventy bio

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Citizens Capital Markets

JMP Securities

HC Wainwright & Co.

Goldman Sachs

Comments

DBV Technologies

DBV Technologies (DBVT) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell